OMP Positioned Highest for Ability to Execute in the 2025 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions
ANTWERPEN, BE / ACCESS Newswire / April 17, 2025 / OMP, a global leader in supply chain planning solutions, has been named a Leader in the Gartner Magic Quadrant for the 10th consecutive time. Positioned highest for 'Ability to Execute,' OMP believes this recognition underscores its consistent delivery of innovative solutions and measurable business results to global supply chains.
A proven platform for the most complex planning needs
OMP attributes its continued advancement to the strength of Unison Planning™, a proven platform for all supply chain planning needs - from strategic to operational, and from demand to supply. As an open, cloud-native, and AI-driven platform, Unison Planning is designed to meet the evolving demand of dynamic global supply chains. It empowers businesses to make smarter, faster decisions and collaborate more effectively across complex networks.
"Today's supply chain leaders must make decisions at the speed of business to stay competitive. It's the only way to deal with tariffs, geopolitical shifts, and disruptions, while also harnessing new opportunities," says Philip Vervloesem, Chief Commercial & Markets Officer at OMP.
Smarter, faster planning with AI at the core
OMP's decision-centric planning approach leverages AI to generate realistic scenarios, helping business leaders keep their supply chain agile and resilient.
"Unison Planning enables businesses to make data-driven decisions more efficiently," says Tom Wouters, Chief Product Officer at OMP. "Our AI-powered approach proactively optimizes supply chain operations, while OMP Companion, our generative AI assistant, drives user adoption and collaboration to unlock the platform's full value."
Co-innovation in action
OMP's innovation strategy is rooted in close collaboration with its customers, ensuring that the platform evolves in direct response to the real-world challenges faced by global supply chains.
"We're excited about our co-innovation initiatives, which deliver real results for our long-term customers and partners," adds Philip Vervloesem. "We believe this year's position validates our approach of solving our customers' toughest challenges together and driving growth across our ecosystem."
Customer success through strategic long-term partnerships
Trusted by Fortune 500 companies, such as AstraZeneca, Dow, Johnson & Johnson, and Nestlé, OMP continues to deliver scalable results across industries through strong partnerships.
"We're proud of our trusted partnerships with leading global companies within our target industries," says Paul Vanvuchelen, CEO of OMP. "I strongly believe this recognition reflects the value of 40 years of deep supply chain planning expertise, and I thank our dedicated teams, loyal customers, and alliance partners for their continued support."
About the Gartner Magic Quadrant
The 2025 Gartner Magic Quadrant for Supply Chain Planning Solutions, released in April 2025, evaluates vendors based on their Ability to Execute and Completeness of Vision, helping business leaders identify the right partners in a complex and fast-evolving market.
For more information about OMP's position as a Leader in the Gartner Magic Quadrant and the future of supply chain planning, read the full report here.
Contact Information
Philip VervloesemSenior Vice President OMP USApvervloesem@omp.com+1-770-956-2723
SOURCE: OMP
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
26 minutes ago
- Medscape
Merck's Potential Blockbuster Cholesterol Pill Succeeds in Late-stage Studies
(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines. The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade. Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes. Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol. BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies. The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said. However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial. Merck has not given the details on LDL-C reduction for enlicitide. The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin. Shares of Merck were up 2% in premarket trading. Verve Therapeutics is also developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs. (Reporting by Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli)
Yahoo
34 minutes ago
- Yahoo
Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance
Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology Enhanced cross-platform compatibility helps simplify device integration, increase longevity of capital equipment, reduce customization development time and lower costs The first of several Phillips Medisize–branded medical connectors planned to launch over the next 18–24 months, TheraVolt™ provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with Phillips Medisize's 60+ years of medical experience HUDSON, Wis., June 09, 2025--(BUSINESS WIRE)--Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of medtech, pharmaceutical drug delivery and in vitro diagnostic devices, announces the launch of TheraVolt™ Medical Connectors. As the first medical connectors launched under the Phillips Medisize brand, TheraVolt is engineered to optimize device integration, functionality, reliability and performance. TheraVolt provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines. Emerging trends in electrophysiology (EP), most notably the rapid adoption of pulsed field ablation (PFA) technology, are driving increased demand for advanced medical connectors that support higher pin count densities and compact design. With enhanced cross-platform compatibility, TheraVolt Medical Connectors help simplify medical device integration, increase longevity of capital equipment, reduce customization development time and lower costs. This can enable more efficient solutions and greater flexibility for medical device companies developing PFA treatment for patients living with atrial fibrillation. "With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers," said Pete Soupir, vice president, MedTech segment at Phillips Medisize. "TheraVolt Medical Connectors empower our medical device customers to develop next-gen EP devices with enhanced integration, connectivity and performance. Their high pin count and high voltage clearance is particularly valuable in medical devices used in electrophysiology treatments, with multiple therapy options, complex functions and expanded data collection." These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with more than 60 years of medical experience from Phillips Medisize. TheraVolt Medical Connectors support next-generation medical device integration and performance through: High Pin Count and Voltage Clearance: Enables the integration of more functionalities, allowing medical device engineers to design multi-therapy medical devices with expanded capabilities, advanced functions and increased data collection. Design Flexibility and Customization: Available off-the-shelf with the flexibility to be tailored to meet diverse application demands, with customizable configurations for specific pin counts and precise electrical requirements. Sterilization Compatibility: Engineered to withstand multiple autoclave cycles, maintaining integrity and performance even under repeated exposure to harsh sterilization processes. Safety and Reliability: Designed to support compliance with IEC and IPC requirements, helping to promote dependable operation in medical applications. Additional Phillips Medisize Medical Connectors are in development and will be delivered over the next 18–24 months. Learn more about TheraVolt Medical Connectors at and About Phillips Medisize Phillips Medisize, a Molex company, collaborates with leading medical technology, pharmaceutical and in vitro diagnostic companies to design, engineer and manufacture lifesaving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to collaborate with customers to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit About Molex Molex is a global electronics leader committed to making the world a better, more-connected place. With a presence in more than 38 countries, Molex enables transformative technology innovation in the consumer device, aerospace and defense, data center, cloud, telecommunications, transportation, industrial automation, and healthcare industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit View source version on Contacts Media Contact: Merryman CommunicationsHelen Winklerhelen@
Yahoo
35 minutes ago
- Yahoo
Patero Announces Launch of CryptoQoR Post-Quantum Cryptography Software
PQC solution can be immediately deployed into existing infrastructure to remediate risks associated with quantum attacks. COLLEGE PARK, Md., June 09, 2025--(BUSINESS WIRE)--Patero, a leader in post-quantum cryptography (PQC), today announced the launch CryptoQoR™. This new highly efficient crypto-agile software module establishes secure communication channels and proactively mitigates security risks using hybrid post-quantum encryption. The solution can be readily deployed into existing infrastructure to improve current cryptographic protection and immediately remediate risks associated with quantum attacks. The post-quantum cryptography (PQC) market is projected to grow from $302.5 million in 2024 to $1,887.9 million by 2029.1 The approach to "Q-day," the day when quantum computers can be used to break traditional encryption, is accelerating with daily advances in quantum computing, quantum switching, AI, and high-performance computing. The migration to PQC is an imperative to secure sensitive data against future quantum threats. Governments and regulatory bodies have mandated the transition to PQC, which includes the adoption of post-quantum cryptographic solutions such as those offered by Patero. "Today's encryption is already obsolete. Using Shor's algorithm, Quantum computers will decrypt data encrypted with asymmetric algorithms such as RSA or Elliptic Curve. Your data is no longer safe," said Patero Chief Executive Officer, Crick Waters. "Sensitive, long-life data is being stolen every day to be decrypted tomorrow by cryptographically relevant quantum computers." Patero CryptoQoR also cloaks Internet-exposed endpoints, making it extremely difficult to find network attack surfaces while protecting businesses from quantum vulnerabilities. CryptoQoR's cloaking feature, therefore, is a key element of Zero Trust network architectures. CryptoQoR utilizes a certificateless authentication method to establish trust and authentication between endpoints. Untrusted endpoints are ignored. Only trusted endpoints, those with quantum-key authentication, are trusted to establish quantum-resistant tunnels. This zero-trust framework reduces network attack surfaces and enhances overall data security. Waters added, "CryptoQoR is also a crypto-agile software solution. It provides software-selectable PQC algorithms, allowing users to select their preferred algorithms in situ or upgrade to new quantum-resistant algorithms without requiring product recall or equipment replacement. All cryptography is eventually broken, but CryptoQoR's agility future-safes networks." About Patero Patero is a leader in quantum secure communications. Patero's cryptographic discovery and inventory solution quantifies risk and prioritizes mitigation of vulnerabilities against present and future cryptographic attacks. Patero's crypto-agile post-quantum security solutions hybridize classic encryption with NIST-standardized quantum-resistant encryption algorithms to mitigate cryptographic vulnerabilities and protect data-in-motion from steal-now, decrypt-later, and future direct decryption attacks. Patero is privately held and based in the Quantum Startup Foundry at the University of Maryland, College Park. For more information, visit For investment opportunities, contact company CEO Crick Waters at crick@ Learn more at 1 Quantum Cryptography Market Forecast to 2030. MarketsandMarkets. October 2024. View source version on Contacts Media Contact: RedIron PR for PateroKari Ritaccokari@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
